newsletter | February 2017 issue 55 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]
newsletter | January 2017 issue 54 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]
newsletter | November 2016 issue 53 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]
newsletter | November 2016 issue 53 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]
ASBM Survey Shows Latin American Physicians Support Distinguishable Names As the annual meeting of the Drug Information Association (DIA) June 15-18 in Washington DC, John Lewis of ASBM Steering Committee member the Association of Clinical Research Organizations (ACRO) presented data from ASBM’s physician surveys. The surveys, of specialists in 11 countries from practice areas in which […]
WHO Meetings in Geneva ASBM Chairman Harry Gewanter, M.D. and International Advisory Board Chair and pharmacist, Philip J. Schneider, M.S., F.A.S.H.P., jointly presented at the World Health Organization’s (WHO) 60th International Nonproprietary Naming Stakeholders Session on April 13 in Geneva. The two provided perspectives from both a physician and pharmacist viewpoint and offered support […]
WHO Meetings in Geneva ASBM Chairman Harry Gewanter, M.D. and International Advisory Board Chair and pharmacist, Philip J. Schneider, M.S., F.A.S.H.P., jointly presented at the World Health Organization’s (WHO) 60th International Nonproprietary Naming Stakeholders Session on April 13 in Geneva. The two provided perspectives from both a physician and pharmacist viewpoint and offered support […]
Labeling Survey Released as FDA Makes First Approval On March 23, ASBM Executive Director Michael Reilly, presented at “The State of Autoimmune Disease: a National Summit” held at the National Press Club and hosted by the American Autoimmune Related Diseases Association. During his presentation, he released the findings from ASBM’s new biosimilar labeling survey that reveals […]
State Update As states are beginning their legislative sessions for the year, there are many biosimilar bills that have been introduced. ASBM supports legislation that encourages open communication between physicians and pharmacists where physicians know exactly which product is dispensed to patients. We applaud the many states that are including this important provision and […]
State Update As states are beginning their legislative sessions for the year, there are many biosimilar bills that have been introduced. ASBM supports legislation that encourages open communication between physicians and pharmacists where physicians know exactly which product is dispensed to patients. We applaud the many states that are including this important provision and […]
